CNS Pharmaceuticals, Inc. SEC filings CNSP
CNS Pharmaceuticals, Inc. has 390 filings in SEC EDGAR's recent list, going back to Mar 13, 2018. Its latest annual report, Form 10-K, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 2, 2026 (officer or director change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B3 | Prospectus | May 26, 2026 | — |
| S-3 | Shelf registration | May 19, 2026 | — |
| S-8 | Employee stock plan registration | Feb 27, 2026 | — |
| 424B5 | Prospectus supplement | Sep 19, 2025 | — |
| 424B4 | Prospectus | May 14, 2025 | — |
| S-1/A | Amended registration statement | May 12, 2025 | — |
| S-1 | Registration statement | Apr 14, 2025 | — |
| 424B5 | Prospectus supplement | Mar 20, 2025 | — |
| 424B5 | Prospectus supplement | Oct 24, 2024 | — |
| 424B3 | Prospectus | Jul 30, 2024 | — |
| 424B5 | Prospectus supplement | Jul 26, 2024 | — |
| S-1/A | Amended registration statement | Jul 19, 2024 | — |
| S-1 | Registration statement | Jul 12, 2024 | — |
| 424B5 | Prospectus supplement | Jul 5, 2024 | — |
| 424B5 | Prospectus supplement | Jun 27, 2024 | — |
| 424B5 | Prospectus supplement | Jun 17, 2024 | — |
| S-1 | Registration statement | Jun 10, 2024 | — |
| S-3 | Shelf registration | May 9, 2024 | — |
| 424B4 | Prospectus | Jan 31, 2024 | — |
| S-1/A | Amended registration statement | Jan 22, 2024 | — |
| S-1/A | Amended registration statement | Jan 10, 2024 | — |
| S-1 | Registration statement | Dec 8, 2023 | — |
| 424B3 | Prospectus | Nov 30, 2023 | — |
| S-8 | Employee stock plan registration | Nov 22, 2023 | — |
| S-3 | Shelf registration | Nov 20, 2023 | — |
| 424B4 | Prospectus | Dec 5, 2022 | — |
| S-1/A | Amended registration statement | Nov 28, 2022 | — |
| S-1/A | Amended registration statement | Nov 15, 2022 | — |
| S-1 | Registration statement | Oct 21, 2022 | — |
| 424B3 | Prospectus | Feb 1, 2022 | — |
| S-3 | Shelf registration | Jan 20, 2022 | — |
| 424B5 | Prospectus supplement | Feb 12, 2021 | — |
| S-3 | Shelf registration | Jan 27, 2021 | — |
| 424B4 | Prospectus | Dec 23, 2020 | — |
| S-1/A | Amended registration statement | Dec 22, 2020 | — |
| S-1 | Registration statement | Dec 21, 2020 | — |
| 424B3 | Prospectus | Oct 7, 2020 | — |
| S-1 | Registration statement | Sep 25, 2020 | — |
| S-8 | Employee stock plan registration | Jul 22, 2020 | — |
| 424B4 | Prospectus | Nov 8, 2019 | — |
| FWP | Free writing prospectus | Oct 15, 2019 | — |
| FWP | Free writing prospectus | Oct 10, 2019 | — |
| S-1/A | Amended registration statement | Oct 7, 2019 | — |
| S-1/A | Amended registration statement | Aug 22, 2019 | — |
| FWP | Free writing prospectus | Jul 16, 2019 | — |
| S-1/A | Amended registration statement | Jul 16, 2019 | — |
| S-1 | Registration statement | Jun 28, 2019 | — |
Showing 47 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CNSP (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NV
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1729427
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.